Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
NCT06658782 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-09-22
Summary
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer.
Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound.
Design and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.
Conditions
- Cirrhosis
- Cirrhosis Due to Hepatitis B
- Cirrhosis and Chronic Liver Disease
- Cirrhosis Due to Hepatitis C
- Cirrhosis of the Liver
- Hepatocellular Carcinoma
Interventions
- DIAGNOSTIC_TEST
-
non contrast enhanced MRI
6 monthly non contrast enhance MRI
Sponsors & Collaborators
-
Bournemouth University
collaborator OTHER -
Glasgow Caledonian University
collaborator OTHER -
Nottingham University Hospitals NHS Trust
collaborator OTHER -
University of Nottingham
collaborator OTHER -
University of Oxford
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-01
- Primary Completion
- 2029-04-30
- Completion
- 2039-04-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Abbreviated MRI for HCC Surveillance
NCT03731923 ·Status: UNKNOWN ·Phase: NA
-
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
NCT04455932 ·Status: RECRUITING ·Phase: NA
-
Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis
NCT00848952 ·Status: UNKNOWN ·Phase: NA
-
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
NCT04212286 ·Status: COMPLETED ·Phase: NA
-
MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH)
NCT04227782 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance
NCT02854241 ·Status: UNKNOWN ·Phase: NA
-
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
NCT03892681 ·Status: UNKNOWN ·Phase: NA
-
Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis
NCT06663904 ·Status: COMPLETED
-
Improving Hepatocellular Carcinoma Screening
NCT05828446 ·Status: RECRUITING ·Phase: NA
-
By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation
NCT03880721 ·Status: UNKNOWN
-
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
NCT05486572 ·Status: RECRUITING ·Phase: NA
-
MRI in Portal Hypertension
NCT01756859 ·Status: UNKNOWN
-
LEAF(Liver Tumor dEtection And classiFication AI)
NCT06859840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
NCT04288323 ·Status: COMPLETED ·Phase: PHASE4
-
Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis
NCT03318380 ·Status: COMPLETED ·Phase: NA
-
Comparison of Multiphase and Monophasic Arterial Hepatic MRI in the Detection of Arterial Enhancement of CHC Nodules
NCT04687280 ·Status: COMPLETED
-
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
NCT02936856 ·Status: UNKNOWN ·Phase: NA
-
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
NCT07055048 ·Status: NOT_YET_RECRUITING
-
Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility
NCT03342677 ·Status: UNKNOWN ·Phase: NA
-
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NCT06537193 ·Status: RECRUITING ·Phase: NA
-
Functional MRI to Determine Severity of Cirrhosis
NCT03623360 ·Status: UNKNOWN
-
Ultrasound and Attenuation Imaging
NCT06552377 ·Status: COMPLETED
-
Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS
NCT06590948 ·Status: RECRUITING
-
Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
NCT03267290 ·Status: COMPLETED ·Phase: NA
-
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
NCT03894917 ·Status: RECRUITING